CR10325A - Diagnosticos y tratamientos para tumores - Google Patents

Diagnosticos y tratamientos para tumores

Info

Publication number
CR10325A
CR10325A CR10325A CR10325A CR10325A CR 10325 A CR10325 A CR 10325A CR 10325 A CR10325 A CR 10325A CR 10325 A CR10325 A CR 10325A CR 10325 A CR10325 A CR 10325A
Authority
CR
Costa Rica
Prior art keywords
tumors
diagnostics
treatments
methods
diagnosing
Prior art date
Application number
CR10325A
Other languages
English (en)
Spanish (es)
Inventor
Megan Baldwin
Napoleone Ferrara
Hans-Peter Gerber
Farbod Shojael
Cuiling Zhong
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of CR10325A publication Critical patent/CR10325A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
CR10325A 2006-03-29 2008-09-29 Diagnosticos y tratamientos para tumores CR10325A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US78772006P 2006-03-29 2006-03-29

Publications (1)

Publication Number Publication Date
CR10325A true CR10325A (es) 2008-12-03

Family

ID=38564192

Family Applications (1)

Application Number Title Priority Date Filing Date
CR10325A CR10325A (es) 2006-03-29 2008-09-29 Diagnosticos y tratamientos para tumores

Country Status (19)

Country Link
US (2) US20070264193A1 (enExample)
EP (1) EP1999151A2 (enExample)
JP (1) JP2009531463A (enExample)
KR (1) KR20080106946A (enExample)
CN (1) CN101448856A (enExample)
AR (1) AR060228A1 (enExample)
AU (1) AU2007233237A1 (enExample)
BR (1) BRPI0709425A2 (enExample)
CA (1) CA2647430A1 (enExample)
CL (1) CL2007000876A1 (enExample)
CR (1) CR10325A (enExample)
IL (1) IL193842A0 (enExample)
MA (1) MA30348B1 (enExample)
MX (1) MX2008012279A (enExample)
NO (1) NO20084546L (enExample)
RU (1) RU2008142775A (enExample)
TW (1) TW200806322A (enExample)
WO (1) WO2007115045A2 (enExample)
ZA (1) ZA200807590B (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10254601A1 (de) 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
DE102004024617A1 (de) 2004-05-18 2005-12-29 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
WO2006094014A2 (en) 2005-02-28 2006-09-08 The Regents Of The University Of California Methods for diagnosis and treatment of endometrial cancer
US8318906B2 (en) 2005-04-15 2012-11-27 The Regents Of The University Of California EMP2 antibodies and their therapeutic uses
EP1790664A1 (en) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
AU2008219216A1 (en) * 2007-02-21 2008-08-28 Ablynx N.V. Amino acid sequences directed against vascular endothelial growth factor and polypeptides comprising the same for the treatment of conditions and diseases characterized by excessive and/or pathological angiogenesis or neovascularization
JP5580205B2 (ja) * 2007-11-19 2014-08-27 セレラ コーポレーション 肺癌マーカーとその使用
WO2009075768A2 (en) * 2007-12-07 2009-06-18 Children's Hospital Of Orange County Optical device and method for real-time chemosensitivity testing
WO2009108360A2 (en) * 2008-02-29 2009-09-03 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of post-radiation tumor growth
WO2010017083A1 (en) * 2008-08-04 2010-02-11 Wayne State University Methods of treating cancer with cd11b antibodies
AR073231A1 (es) * 2008-08-29 2010-10-20 Genentech Inc Metodos diagnosticos y tratamientos para los tumores independientes del vegf (factor de crecimiento endotelial vascular)
US20110190380A1 (en) * 2008-10-23 2011-08-04 Elena Feinstein Methods for delivery of sirna to bone marrow cells and uses thereof
US9498431B2 (en) 2008-12-10 2016-11-22 Jianjian Xu Controlled releasing composition
KR20140020368A (ko) * 2008-12-23 2014-02-18 제넨테크, 인크. 암 환자에서의 진단 목적용 방법 및 조성물
US7615353B1 (en) 2009-07-06 2009-11-10 Aveo Pharmaceuticals, Inc. Tivozanib response prediction
SG178177A1 (en) * 2009-07-31 2012-03-29 Genentech Inc Inhibition of tumor metastasis using bv8- or g-csf-antagonists
JP2013501526A (ja) * 2009-08-14 2013-01-17 ジェネンテック， インコーポレイテッド Ｖｅｇｆアンタゴニストに対する患者の応答をモニターするための生物学的マーカー
US7736861B1 (en) 2009-10-19 2010-06-15 Aveo Pharmaceuticals, Inc. Tivozanib response prediction
JP5911805B2 (ja) 2009-11-20 2016-04-27 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 上皮膜タンパク質−２（ｅｍｐ２）および増殖性硝子体網膜症（ｐｖｒ）
CN102844050B (zh) * 2010-02-19 2019-02-05 康奈尔大学 自身免疫性脱髓鞘疾病及其它自身免疫疾病或炎性疾病的治疗方法
CA2790500A1 (en) * 2010-02-19 2011-08-25 Lynn K. Gordon Epithelial membrane protein 2 (emp2) binding reagents and their therapeutic uses in ocular diseases
KR101313184B1 (ko) * 2010-06-24 2013-09-30 한국표준과학연구원 질병 지표 검출 키트 및 질병 지표 검출 방법
CN103890008A (zh) * 2011-08-17 2014-06-25 霍夫曼-拉罗奇有限公司 在顽固性肿瘤中抑制血管发生
WO2013167153A1 (en) 2012-05-09 2013-11-14 Ganymed Pharmaceuticals Ag Antibodies useful in cancer diagnosis
RU2502471C9 (ru) * 2012-08-21 2015-04-20 Федеральное бюджетное учреждение науки "Федеральный научный центр медико-профилактических технологий управления рисками здоровью населения" (ФБУН "ФНЦ медико-профилактических технологий управления рисками здоровью населения") Способ оценки соответствия размеров селезенки норме или отклонению от нее у детей методом ультразвуковой диагностики
EP2741086A1 (en) * 2012-12-06 2014-06-11 Ludwig Boltzmann Gesellschaft Method for measuring coagulation of blood samples using viscoelastic tests (VET)
WO2014127785A1 (en) * 2013-02-20 2014-08-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2014159923A1 (en) * 2013-03-13 2014-10-02 Health Research, Inc. Enhancement of vaccines
RU2546105C1 (ru) * 2014-04-29 2015-04-10 Федеральное бюджетное учреждение науки "Федеральный научный центр медико-профилактических технологий управления рисками здоровью населения" (ФБУН "ФНЦ медико-профилактических технологий управления рисками здоровью населения") Способ оценки методом ультразвуковой диагностики соответствия размеров селезенки норме или отклонению от нее у детей от 3 до 15 лет
EP3532498A1 (en) * 2016-10-31 2019-09-04 Hexal AG Antibody preparation
US20210322314A1 (en) * 2018-07-24 2021-10-21 Avinash Seth Use Of Liposomes To Deliver A Protein And A Gene Encoding The Protein To A Live Cell
US20200347449A1 (en) * 2019-05-01 2020-11-05 The Broad Institute, Inc. Methods for determining spatial and temporal gene expression dynamics during adult neurogenesis in single cells
CN112946291A (zh) * 2019-12-10 2021-06-11 上海交通大学医学院附属仁济医院 Fgf18在制备诊断和预测卵巢癌试剂中的应用及fgf18化学发光检测试剂盒

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4840793A (en) * 1987-06-11 1989-06-20 Dana-Farber Cancer Institute Method of reducing tissue damage at an inflammatory site using a monoclonal antibody
US6582959B2 (en) * 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
US20030206899A1 (en) * 1991-03-29 2003-11-06 Genentech, Inc. Vascular endothelial cell growth factor antagonists
US20020032313A1 (en) * 1991-03-29 2002-03-14 Genentech, Inc. Vascular endothelial cell growth factor antagonists
WO1994004679A1 (en) * 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
DE4422551C1 (de) * 1994-06-28 1995-07-27 Daimler Benz Ag Durch Servomotor unterstützte Zahnstangenlenkung
US5871697A (en) * 1995-10-24 1999-02-16 Curagen Corporation Method and apparatus for identifying, classifying, or quantifying DNA sequences in a sample without sequencing
ES2273415T3 (es) * 1997-04-07 2007-05-01 Genentech, Inc. Anticuerpos anti-vegf.
US20020032315A1 (en) * 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
US6884879B1 (en) * 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
AU4972900A (en) * 1999-04-08 2000-11-14 Arch Development Corporation Use of anti-vegf antibody to enhance radiation in cancer therapy
US6703020B1 (en) * 1999-04-28 2004-03-09 Board Of Regents, The University Of Texas System Antibody conjugate methods for selectively inhibiting VEGF
HRP20030041A2 (en) * 2000-06-23 2005-02-28 Schering Aktiengesellschaft Combinations and compositions which interfere with vegf/vegf and angiopoietin/tie receptor fuction and their use (ii)
AU2003215163A1 (en) * 2002-02-12 2003-09-04 Vanderbilt University Inhibition of vegf receptor signaling reverses tumor resistance to radiotherapy
RS20150135A1 (sr) * 2003-05-30 2015-08-31 Genentech Inc. Tretman sa anti-vegf antitelima
WO2005044853A2 (en) * 2003-11-01 2005-05-19 Genentech, Inc. Anti-vegf antibodies
US20060009360A1 (en) * 2004-06-25 2006-01-12 Robert Pifer New adjuvant composition

Also Published As

Publication number Publication date
IL193842A0 (en) 2011-08-01
CA2647430A1 (en) 2007-10-11
WO2007115045A2 (en) 2007-10-11
KR20080106946A (ko) 2008-12-09
JP2009531463A (ja) 2009-09-03
BRPI0709425A2 (pt) 2011-07-12
MA30348B1 (fr) 2009-04-01
CN101448856A (zh) 2009-06-03
NO20084546L (no) 2008-12-23
AU2007233237A1 (en) 2007-10-11
CL2007000876A1 (es) 2008-02-08
TW200806322A (en) 2008-02-01
MX2008012279A (es) 2008-10-08
US20070264193A1 (en) 2007-11-15
WO2007115045A3 (en) 2008-04-03
US20100239568A1 (en) 2010-09-23
RU2008142775A (ru) 2010-05-10
ZA200807590B (en) 2009-11-25
EP1999151A2 (en) 2008-12-10
AR060228A1 (es) 2008-06-04

Similar Documents

Publication Publication Date Title
CR10325A (es) Diagnosticos y tratamientos para tumores
MX2017013178A (es) Terapia de combinacion para cancer.
CY1126115T1 (el) Συνδυασμος anti-lag-3 αντισωματων και anti-pd-1 αντισωματων για θεραπεια ογκων
CL2011001255A1 (es) Combinaciones farmaceutica que comprende un anticuerpo que reconoce especificamente cd38 y al menos vincristina; y uso del anticuerpo que reconoce especificamente cd38 para el tratamiento del cancer.
MX2020006668A (es) Anticuerpos para lilrb2.
CL2017001580A1 (es) Anticuerpo o fragmento de anticuerpo contra cd38 anticuerpo humanizado, conjugado del anticuerpo con un compuesto citotoxico composición farmacéutica con dichos anticuerpos uso de los anticuerpos para tratar cáncer o enfermedad autoinmune método para diagnosticar cáncer polinucleotido vector y célula huésped.
EA201300810A1 (ru) Противораковая терапия с использованием двойных ингибиторов киназ аврора/мек
MX2016015363A (es) Terapias de combinacion para el tratamiento de cancer.
MX2017008421A (es) Métodos terapéuticos, diagnósticos y pronósticos para el cáncer de vejiga.
CY1119112T1 (el) K-ras μεταλλαξεις και θεραπεια anti-egfr αντισωματος
AR062419A1 (es) Terapia tumoral con un anticuerpo anti- vegf
AU2017228470A8 (en) Combination therapy with anti-CD73 antibodies
BR112016017256A2 (pt) combinação de um antagonista de pd-1 e um inibidor de vegfr para o tratamento de câncer
EA200970317A1 (ru) Комбинированное лечение опухолей, экспрессирующих cd38
MX395149B (es) Terapias de combinación que comprenden un receptor quimérico de antígeno cd19 para el cáncer.
AR077866A1 (es) Terapia de combinacion de un anticuerpo cd20 afucosilado y bendamustina
CR20120454A (es) Proteínas terapéuticas de unión a dll4
CR20170096A (es) Tratamientos conjuntos con anticuerpos anti cd40
MX383886B (es) Anticuerpo anti-trop-2 humano que tiene una actividad antitumoral in vivo.
MX2015007189A (es) Composiciones que comprenden anticuerpos anti-cd38 y lenalidomida.
MX374290B (es) Combinación de un anticuerpo anti cd20 con un inhibidor de btk para usarse en el tratamiento de cáncer.
CR20110553A (es) Terapia complementaria contra el cáncer
CL2025000404A1 (es) Anticuerpo anti-lilrb1 y usos del mismo
BR112014011925A2 (pt) mutações no receptor notch humano e seu uso
WO2015073896A3 (en) Biomarkers for psma targeted therapy for prostate cancer

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)